Preparation and characterization of coenzyme Q10-loaded PMMA nanoparticles by a new emulsification process based on microfluidization

Colloids and Surfaces A: Physicochemical and Engineering Aspects

Volumn 210, Issue 1, 2002, Pages 95-104

  Kwon, Sun Sang ^a   Nam, Yoon Sung ^a   Lee, Jong Suk ^a   Ku, Bong Seok ^a   Han, Sang Hoon ^a   Lee, Jang Young ^a   Chang, Ih Seop ^a  

^a AmorePacific Corporation   (South Korea)

Author keywords

Coenzyme Q10; Drug stability; Microfluidization; Nanoparticles; Poly(methyl methacrylate)

Indexed keywords

CRYSTAL STRUCTURE; DRUG PRODUCTS; EMULSIFICATION; EVAPORATION; FLUIDIZATION; LIGHT SCATTERING; POLYMETHYL METHACRYLATES; SOLVENTS; SURFACE ACTIVE AGENTS; TRANSMISSION ELECTRON MICROSCOPY;

MICROFLUIDIZATION;

COENZYMES;

NANOPARTICLE; POLY(METHYL METHACRYLATE); SURFACTANT; UBIDECARENONE;

AQUEOUS SOLUTION; ARTICLE; CRYSTAL STRUCTURE; DIFFERENTIAL SCANNING CALORIMETRY; DISPERSION; DRUG SYNTHESIS; EMULSION; ENCAPSULATION; FLUIDIZATION; LIGHT SCATTERING; MELTING POINT; PARTICLE SIZE; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; REPRODUCIBILITY; TRANSMISSION ELECTRON MICROSCOPY; ULTRAVIOLET RADIATION;

EID: 0037121041     PISSN: 09277757     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0927-7757(02)00212-1     Document Type: Article

References (18)

1. Soppimath K.S., Aminabhavi T.M., Kulkarni A.R., Rudzinski W.E. Biodegradable polymeric nanoparticles as drug delivery devices. J. Control Rel. 70:2001;1-20.
2. Couvreur P., Vauthier C. Polyalkylcyanoacrylate nanoparticles as drug carrier: present state and perspectives. J. Control Rel. 17:1991;187-198.
3. Gibaud S., Rousseau C., Weingarten C., Favier R., Douay L., Andreux J.P., Couvreur P. Polyalkylcyanoacrylate nanoparticles as carriers for granulocyte-colony stimulating factor (G-CSF). J. Control Rel. 52:1998;131-139.
4. Espuelas M.S., Legrand P., Irache J.M., Gamazo C., Orecchioni A.M., Devissaguet J.-Ph, Ygartua P. Poly(ε-caprolactone) nanospheres as an alternative way to reduce amphotericin B toxicity. Int. J. Pharm. 158:1997;19-27.
5. Yoo H.S., Oh J.E., Lee K.H., Park T.G. Biodegradable nanoparticles containing doxorubicin-PLGA conjugate for sustained release. Pharm. Res. 16:(7):1999;1114-1118.
6. Jung J., Perrut M. Particle design using supercritical fluids: literature and patent survey. J. Supercrit. Fluids. 20:2001;179-219.
7. Zambaux M.F., Bonneaux F., Gref R., Maincent P., Dellacherie E., Alonso M.J., Labrude P., Vigneron C. Influence of experimental parameters on the characteristics of poly(lactic acid) nanoparticles prepared by double emulsion method. J. Control Rel. 50:1998;31-40.
8. Kwon H.Y., Lee J.Y., Choi S.W., Jang Y., Kim J.H. Preparation of PLGA nanoparticles containing estrogen by emulsification-diffusion method. Colloids and Surfaces A: Physicochem. Eng. Aspects. 182:2001;123-130.
9. Bodmeier R., Chen H. Indomethacin polymeric nanosuspensions prepared by microfluidization. J. Control Rel. 12:1990;223-233.
10. Bodmeier R., Chen H. Hydrolysis of cellulose acetate and cellulose acetate butylate pseudolatexes prepared by a solvent evaporation-microfluidization method. Drug Dev. Ind. Pharm. 19:(5):1993;521-530.
11. 10 supplementation on the oxidation resistance of human VLDL+LDL fraction: absorption and antioxidative properties of oil and granule-based preparations. Free Radic. Biol. Med. 22:(7):1997;1195-1202.
12. 10. 5:1986;375-391 Elsevier, Amsterdam.
13. 10 in beagle dogs. Chem. Pharm. Bull. 47:(7):1999;1024-1028.
14. 10: formulation development and bioavailability assessment. Int. J. Pharm. 212:2001;233-246.
15. 10: a new drug for cardiovascular disease. J. Clin. Pharmacol. 30:1990;596-608.
16. 10 increases myocardial tissue levels and improves tolerance to ischemia reperfusion injury. J. Surgical Res. 79:1998;141-145.
17. Inactive Ingredient Guide (Redacted), U.S. Food and Drug Administration, Center for Drug Evaluation and Research (1996) 133-134.
18. 10-eudragit® solid dispersion, Proceedings of the 28th International Symposium on Controlled Release of Bioactive Materials, San Diego, California, 23-27 June 2001, Controlled Release Society, #6112.